Raloxifene
CAS: 84449-90-1
Ref. 3D-FR175031
1g | 1.382,00 € | ||
50mg | 325,00 € | ||
100mg | 452,00 € | ||
250mg | 723,00 € | ||
500mg | 1.136,00 € |
Información del producto
- [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone
- Methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-
- Keoxifene
- LY 139481
Raloxifene is a non-steroidal drug that binds to estrogen receptors, which may be useful in the treatment of postmenopausal osteoporosis. Raloxifene has been shown to increase bone mineral density and reduce the risk of vertebral fractures in postmenopausal women with osteoporosis. Raloxifene also has been found to decrease breast cancer risk by about 50% in postmenopausal women. The drug binds to estrogen receptors in breast tissue, preventing the stimulation of these cells by estrogen and decreasing their growth rate. Raloxifene also inhibits the production of lactogenic hormones such as prolactin and progesterone that are involved in breast cancer development. Raloxifene hydrochloride is used at doses between 60 mg and 120 mg per day for a duration of 5 years.
Raloxifene hydrochloride is not active against estrogen receptor positive tumors and should not be used for treatment of breast cancer.
Propiedades químicas
Consulta técnica sobre: 3D-FR175031 Raloxifene
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.